My ePortfolio Register   

Outcome of third salvage autologous stem cell transplantation in multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.03.17
Views: 433
Rating:

Dr Laurent Garderet - Hôpital Saint Antoine, Paris, France

Dr Garderet speaks with ecancer at the 16th International Myeloma Workshop about the outcome of third salvage autologous stem cell transplantation in multiple myeloma.

Autologous stem cell transplantation remains a standard treatment for younger patients with multiple myeloma. 

With the aid of new drugs, the patients live longer and third salvage ASCT is an increasingly used option.

However, the outcome of third salvage autologous stem cell transplantation has not yet been analysed. 

Dr Garderet also spoke with ecancer about his highlights of the conference here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence